Oral vaccines are gaining more attention due to their ease of administration, lower invasiveness, generally greater safety, and lower cost than injectable vaccines. This review introduces certified oral vaccines for adenovirus, recombinant protein-based, and transgenic plant-based oral vaccines, and their mechanisms for inducing an immune response. Procedures for regulatory approval and clinical trials of injectable and oral vaccines are also covered. Challenges such as instability and reduced efficacy in low-income countries associated with oral vaccines are discussed, as well as recent developments, such as Bacillus-subtilis-based and nanoparticle-based delivery systems that have the potential to improve the effectiveness of oral vaccines.

Microalgae-based biodiesel is increasingly recognized as an alternative to crop-based biodiesel. In this study, 10 local strains of dinoflagellates collected from Hong Kong waters, including a monoculture and field sample of Scrippsiella sp. isolated from an algal bloom, were evaluated against the performance of green alga Tetraselmis suecica. The specific growth rate, biomass production, lipid productivity, and fatty acid profile were investigated. The total lipid content of isolated strains ranged from 16.2% to 32.2% of the total dry biomass, whereas palmitic acid (C16:0) and docosahexaenoic acid (DHA, C22:6n3) were dominant in the fatty acid profile. Scrippsiella sp. has a high lipid productivity (47.3 mg/L/day) and fatty acid methyl esters (FAME) content (55.2–73 mg/g dry weight (dw)), which were comparable to that in green alga T. suecica. Further, monoculture and field sampled blooming Scrippsiella sp. showed no significant difference in most parameters, suggesting the possibility of harvesting a natural algal bloom population as a mitigation strategy to harmful algal bloom and to use as biodiesel feedstock. Overall, dinoflagellate species showed a slower growth rate (0.04–0.57 day⁻¹) than most compared species (0.07–1.34 day⁻¹), likely due to a large genome size and low chlorophyll to carbon ratio. Notably, most investigated dinoflagellates were not ideal for mass biodiesel production due to the low growth rate and lipid productivity. However, a high level of polyunsaturated fatty acids (PUFA) in dinoflagellates are prospective for further studies in other biotechnological applications. Though effectively harvesting algal blooming biomass can be complex, it can be further explored as a strategy for algal bloom mitigation and potentially creating values at the advantage of natural bloom when applying harvested biomass for biodiesel and bioactive compounds extraction.

The coronavirus diseases 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have threatened the world for more than 2 years. Multiple vaccine candidates have been developed and approved for emergency use by specific markets, but multiple doses are required to maintain the antibody level. Preliminary safety and immunogenicity data about an oral dose vaccine candidate using recombinant Bacillus subtilis in healthy adults were reported previously from an investigator-initiated trial in Hong Kong. Additional data are required in order to demonstrate the safety and efficacy of the candidate as a heterologous booster in vaccinated recipients. In an ongoing, placebo-controlled, observer-blinded, fixed dose, investigator-initiated trial conducted in the Macau, we randomly assigned healthy adults, 21 to 62 years of age to receive either placebo or a Bacillus subtilis oral dose vaccine candidate, which expressed the spike protein receptor binding domain of SARS-CoV-2 on the spore surface. The primary outcome was safety (e.g., local and systemic reactions and adverse events); immunogenicity was a secondary outcome. For both the active vaccine and placebo, participants received three courses in three consecutive days. A total of 16 participants underwent randomization: 9 participants received vaccine and 7 received placebo. No observable local or systemic side-effect was reported. In both younger and older adults receiving placebo, the neutralizing antibody levels were gradually declining, whereas the participants receiving the antibody booster showed an increase in neutralizing antibody level.